Jeremy G. Chadwick - 22 May 2023 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Operating Officer
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
Issuer symbol
KYMR
Transactions as of
22 May 2023
Net transactions value
$0
Form type
4
Filing time
22 May 2023, 19:35:13 UTC
Next filing
04 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Award $0 +33,333 $0.000000 33,333 22 May 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Award $0 +200,000 $0.000000 200,000 22 May 2023 Common Stock 200,000 $29.64 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Jeremy G. Chadwick is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following May 22, 2023, subject to the reporting person's continued employment through each vesting date.
F2 25% of the shares underlying this stock option shall vest on May 22, 2024, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date.